The updated ASCO guidelines for stage IV NSCLC provide new treatment recommendations based on the latest evidence. Explore these changes and their potential impact on patient care.

The MIRASOL trial has unveiled mirvetuximab soravtansine’s potential to revolutionize the treatment landscape for patients with platinum-resistant ovarian cancer. Physicians are invited to delve into the data that positions this novel therapy as a potential new standard of care.

The FDA’s approval of the olaparib, abiraterone, and prednisone regimen for BRCA-mutated mCRPC, based on the PROpel trial, could significantly alter the treatment landscape. Learn more about this promising development in prostate cancer therapy.

The recent survey by the American Society of Hematology underscores the potential influence of compensation models and support staff on burnout rates among hematologists and oncologists. The findings suggest a need for reevaluating compensation systems and further integrating APPs in clinical practice to enhance physician wellness.

The chemotherapy shortage in the US is a pressing issue that demands a reevaluation of health policies. Dive deeper into the potential strategies for mitigating its impact, from creating a market for high-quality generics to convening a multi-stakeholder task force.

Explore the potential implications of the formation of Risant Health on community oncology, as discussed by industry experts in a recent episode of Cancer Care Business Breakthroughs. Learn about the potential challenges and opportunities this new entity could bring to the healthcare landscape.